The IMpower130 Trial of Carbo/Nab-Paclitaxel +/- Atezolizumab: Does this Positive Trial Change Management? (BMIC-071)

The IMpower130 Trial of Carbo/Nab-Paclitaxel +/- Atezolizumab: Does this Positive Trial Change Management? (BMIC-071)

BeaconMedIC

11 months
689 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Dr. Jack West reviews the IMpower130 trial of carboplatin + nab-paclitaxel with or without atezolizumab as first line treatment for advanced non-squamous NSCLC and whether this positive trial changes management in this setting.
Up Next Autoplay
Top 5 Most Influential Trial Findings in Lung Cancer Management in 2018 (BMIC-073)
Top 5 Most Influential Trial Findings in Lung Cancer Management in 2018 (BMIC-073)
Category: General
1,200 Views
BeaconMedIC 10 months
What does the CheckMate-331 trial of nivolumab vs. chemo for relapsed SCLC tell us? (BMIC-072)
What does the CheckMate-331 trial of nivolumab vs. chemo for relapsed SCLC tell us? (BMIC-072)
Category: Small Cell Lung Cancer
925 Views
BeaconMedIC 10 months
Overall Survival Benefit for Local Ablative Therapy as Consolidation for Oligometastatic Stage IV NSCLC: Where Does it Fit in Practice Now? (BMIC-070)
Overall Survival Benefit for Local Ablative Therapy as Consolidation for Oligometastatic Stage IV NSCLC: Where Does it Fit in Practice Now? (BMIC-070)
Category: Non-Small Cell Lung Cancer
614 Views
BeaconMedIC 11 months
The IMpower132 Trial: Does This Change the Advanced NSCLC Landscape? (BMIC-069)
The IMpower132 Trial: Does This Change the Advanced NSCLC Landscape? (BMIC-069)
Category: Non-Small Cell Lung Cancer
549 Views
BeaconMedIC 11 months
The MYSTIC Trial has Failed on Overall Survival in Advanced NSCLC: What Does and Doesn't This Tell Us? (BMIC-068)
The MYSTIC Trial has Failed on Overall Survival in Advanced NSCLC: What Does and Doesn't This Tell Us? (BMIC-068)
Category: Non-Small Cell Lung Cancer
463 Views
BeaconMedIC 11 months
Pembrolizumab for Patients with Advanced NSCLC and a Performance Status (PS) of 2: Results of the PePS2 Trial (BMIC-067)
Pembrolizumab for Patients with Advanced NSCLC and a Performance Status (PS) of 2: Results of the PePS2 Trial (BMIC-067)
Category: Non-Small Cell Lung Cancer
424 Views
BeaconMedIC 12 months
Long-Term Management of Patients Doing Well on Immunotherapy for Advanced NSCLC: Insights from KEYNOTE-010 (BMIC-066)
Long-Term Management of Patients Doing Well on Immunotherapy for Advanced NSCLC: Insights from KEYNOTE-010 (BMIC-066)
Category: Non-Small Cell Lung Cancer
222 Views
BeaconMedIC 12 months
Updated Results on PACIFIC Trial: Should we Revise Who Should Receive Consolidation Immunotherapy after Chemo/Radiation? (BMIC-065)
Updated Results on PACIFIC Trial: Should we Revise Who Should Receive Consolidation Immunotherapy after Chemo/Radiation? (BMIC-065)
Category: Immunotherapy
257 Views
BeaconMedIC 1 year
IMpower133: Is there Finally a New Standard of Care for Extensive Stage SCLC? (BMIC-064)
IMpower133: Is there Finally a New Standard of Care for Extensive Stage SCLC? (BMIC-064)
Category: Small Cell Lung Cancer
332 Views
BeaconMedIC 1 year